FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease (FRENCH)

This study has been completed.
Sponsor:
Collaborator:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Centre Hospitalier Universitaire, Amiens
ClinicalTrials.gov Identifier:
NCT01220843
First received: October 12, 2010
Last updated: September 2, 2013
Last verified: February 2012

October 12, 2010
September 2, 2013
October 2010
April 2013   (final data collection date for primary outcome measure)
Measurement of the serum levels of C terminal segment of fibroblast growth factor 23 (FGF23) and evaluation of sevelamer carbonate effect on this levels in comparison with placebo [ Time Frame: 12 weeks after the beginning of treatment ] [ Designated as safety issue: No ]
Indeed the sevelamer carbonate could lead to a diminution of FGF23 serum levels due to the diminution of intestinal absorption of dietary phosphate.
Same as current
Complete list of historical versions of study NCT01220843 on ClinicalTrials.gov Archive Site
  • Evaluation of sevelamer carbonate effect on the serum levels of iPTH [ Time Frame: 12 weeks after the beginning of treatment ] [ Designated as safety issue: No ]
  • Evaluation of sevelamer carbonate effect on the serum levels of calcitriol (1 25(OH)2D3) [ Time Frame: 12 weeks after the beginning of treatment ] [ Designated as safety issue: No ]
  • Evaluation of sevelamer carbonate effect on the serum levels of others mineral metabolism parameters (phosphore, calcium, intact FGF-23 , 25(OH)D3, bone specific alkaline phosphatases, osteocalcin, collagen crosslink, C reactive protein) [ Time Frame: 12 weeks after the beginning of treatment ] [ Designated as safety issue: No ]
  • Evaluation of sevelamer carbonate effect on the urinary levels of phosphate [ Time Frame: 12 weeks after the beginning of treatment ] [ Designated as safety issue: No ]
  • Evaluation of sevelamer carbonate effect on the urinary levels of calcium [ Time Frame: 12 weeks after the beginning of treatment ] [ Designated as safety issue: No ]
  • Evaluation of sevelamer carbonate effect on the urinary levels of creatinine [ Time Frame: 12 weeks after the beginning of treatment ] [ Designated as safety issue: No ]
  • Evaluation of sevelamer carbonate effect on the urinary levels of urea [ Time Frame: 12 weeks after the beginning of treatment ] [ Designated as safety issue: No ]
  • Evaluation of sevelamer carbonate effect on the serum and urinary levels of specific biomarkers (serum : fetuin A, para-cresyl sulfate, osteopontin) [ Time Frame: 12 weeks after the beginning of treatment ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
Randomized Placebo Controlled Double-blind Trial in CKD Patients Not on Dialysis to Evaluate the Effect of Sevelamer Carbonate in the Control of FGF-23 Serum Levels and Its Consequences in the Evolution of PTH, Calcitriol and Mineral Metabolism Parameters Levels

The purpose of this study is to evaluate in Chronic Kidney Disease (CKD) patients not on dialysis and who have an Fibroblast growth factor 23 (FGF23) serum levels elevated, the effect of non calcic phosphate binder: sevelamer carbonate. This treatment could lead to a diminution of FGF23 serum levels due to the diminution of intestinal absorption of dietary phosphate. In addition, the investigators will describe the impact of the FGF23 level monitoring on the main phosphocalcium metabolism markers as phosphatemia, intact parathyroid hormone (iPTH), serum calcitriol and phosphaturia.

The total length of the study is 14 weeks divided in 2 parts the first part is the screening period she will stay 1 to 2 weeks and the second period with the treatment with permanent dosage during 12 weeks.

During the screening visit (Vo) inclusion and non inclusion criteria will be checked and the patient consent will be collected. Biological analysis will be performed.

If the patient still eligible after the reception of biological results, he will be randomized and will received, either sevelamer carbonate, either placebo. The study treatment will be begun at the randomisation visit (V1) the dosage will be 2 tablets 3 times per day (corresponding to 4.8g/d sevelamer carbonate for patient taken active medication).

Patient will be seen every 2 weeks after the first visit (+/-5days) during 6 weeks (visit2/day15, visit3/day30, visit4/day45) and 12 weeks after the randomisation visit (visit5/day90). This visits will include biological analysis, compliance evaluation, adverse events report, concomitant treatments reports.

After the consent signature, all the adverse events will be collected until the end of the study for the patient (Visit5 or end of the study visit). Serious adverse events will be collected until 30 days after the date of the end of the study.

The same dosage of the study treatment will be followed during all the study period except if the phosphatemia (evaluated during one analysis) is found above the normal range planned by the protocol. In this case, the dosage adaptations will be :

  • If during a visit the phosphatemia is above or equal to 0.8 mmol/l and superior to 0.5 mmol/l, the study treatment dosage need to be reduce to 2 tablets 3 times per day to 1 tablet 3 times per day.
  • If during the next blood punction, the phosphatemia still or equal to 0.8 mmol/l and superior to 0.5 mmol/l, the study treatment will be stopped and a "end of study" visit will be performed.
  • If during one study visit, the phosphatemia is above or equal to 0.5 mmol/l,the study treatment will be stopped immediately and a end of study visit will be performed.
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Chronic Renal Failure
  • Drug: Placebo
    dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks
    Other Name: Placebo
  • Drug: Sevelamer carbonate
    dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks ( each tablet :800mg sevelamer carbonate
    Other Name: Renvela 800
  • Placebo Comparator: Placebo
    DOuble blinded, same labels than the active drug same dosage (2 tablets 3 times per day) during the meal
    Intervention: Drug: Placebo
  • Experimental: Sevelamer carbonate
    DOuble blinded, dosage 2 tablets 3 times per day corresponding to 4.8/d to taken during meals
    Intervention: Drug: Sevelamer carbonate

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
98
April 2013
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who gave their written consent
  • Women or men over 18 years
  • No concomitant treatment with phosphate binders
  • CKD patients not on dialysis stage 3b or 4, as a GFR (glomerular filtration rate) between 15 and 45 ml/min/1.73m2, using simplified MDRD formula
  • At the inclusion visit,patients with blood results as levels of C-terminal FGF-23 > 120 rU/ml and fasting phosphatemia > 1.0 mmol/l
  • Able to comply with the study procedures during all the study period
  • Willing to abstain from taking any following medication during all the study period :antiacid and phosphate binders with aluminium, magnesium, calcium or lanthanum;Treatment for hyperparathyroid : active vitamin D and calcimimetic ; native vitamin D
  • Female subjects who are of childbearing potential must have a reliable contraceptive methods during all the study period (hormonal, barrier methods or intrauterine device)
  • No Participation in any clinical trial using an investigational product or device during the 30 days preceding the first protocol visit
  • Informed patient who agreed with the utilisation of his data for the study
  • Able to read and understand french and study objectives
  • Inscription to medical assurance

Exclusion Criteria:

  • predisposition with or presence of intestinal or ileus obstruction or severe gastrointestinal motility disorder(like severe constipation)
  • Antecedent of major gastrointestinal surgery
  • Abusive consumption of alcohol and drug (exclude tabacco) according the investigator
  • Arrythmia treated by antiarrythmic agent or epilepsia treated by anticonvulsant
  • Antecedent of kidney transplantation
  • Antecedent of parathyroidectomy
  • At the inclusion visit,patients with blood results as fasting phosphatemia > 1.78 mmol/l or serum 25(OH)D3< 20 ng/ml (<50 nmol/)
  • Pregnancy or breastfeeding
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01220843
Amiens FRENCH, 2010-020872-49
Yes
Centre Hospitalier Universitaire, Amiens
Centre Hospitalier Universitaire, Amiens
Genzyme, a Sanofi Company
Principal Investigator: Gabriel Choukroun, Ph D, M D Centre Hospitalier Universitaire, Amiens
Centre Hospitalier Universitaire, Amiens
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP